Dapkutė Austėja, Vainauskienė Jurgita, Ryliškienė Kristina
Centre of Neurology, Vilnius University, Santariskiu st. 2, 08661, Vilnius, Lithuania.
Centre of Neurology, Kardiolitos klinikos, Laisves pr. 64A, 05263, Vilnius, Lithuania.
Neurol Sci. 2022 May;43(5):3305-3312. doi: 10.1007/s10072-021-05861-4. Epub 2022 Jan 10.
Despite development of new therapies, migraine remains an undertreated illness. It is important to understand patients' preferences and perceptions of using a certain therapy. We present data from a nationwide Lithuanian survey of patients' experience using erenumab for the treatment of high frequency episodic and chronic migraine.
An anonymous internet survey was distributed on February-March 2021 to the members of Migraine Association of Lithuania. All adult respondents who reported using at least one dose of erenumab were included in the study.
Out of 145 respondents, 75.2% had chronic migraine, and 31.7% had medication overuse headache. Patients received an average of 6 (IQR 4-9) erenumab doses. 93.1% respondents found erenumab effective, and 72.6% experienced improvement during the first month. MHDs were reduced by 9.8 (SD 6.0) (P < 0.001), and MMDs by 7.2 (SD 5.2) days (P < 0.001). 78.6% respondents achieved ≥ 50% reduction and 47.6% achieved ≥ 75% reduction of MMDs. 13.8% patients indicated a wearing-off effect during the treatment course, and 37.8% - some wearing-off between injections. Constipation was the most frequent adverse event (32.6%). 47.2% of patients who had a positive erenumab effect and discontinued treatment experienced migraine rebound in 6 (SD 2.0) weeks.
Erenumab is perceived as an effective and safe treatment. Further studies are needed to investigate a post-cessation deterioration of achieved improvement.
• Vast majority of patients experience stable or increasing effect of erenumab. • Erenumab efficacy usually becomes evident during the first month of treatment. • Erenumab is perceived significantly better than non-specific preventive medications. • Almost 40% of patients experienced some wearing-off between injections. • Almost half of patients experience migraine rebounds after treatment cessation.
尽管有了新的治疗方法，但偏头痛仍然是一种治疗不足的疾病。了解患者对使用某种治疗方法的偏好和看法很重要。我们展示了立陶宛一项全国性调查的数据，该调查涉及患者使用erenumab治疗高频发作性和慢性偏头痛的经历。
2021年2月至3月，对立陶宛偏头痛协会成员进行了一项匿名网络调查。所有报告使用过至少一剂erenumab的成年受访者都被纳入研究。
在145名受访者中，75.2%患有慢性偏头痛，31.7%患有药物过度使用性头痛。患者平均接受了6（四分位间距4 - 9）剂erenumab。93.1%的受访者认为erenumab有效，72.6%的受访者在第一个月内病情有所改善。每月头痛天数减少了9.8（标准差6.0）天（P < 0.001），每月偏头痛天数减少了7.2（标准差5.2）天（P < 0.00）。78.6%的受访者每月偏头痛天数减少≥50%，47.6%的受访者减少≥75%。13.8%的患者表示在治疗过程中有药效减退现象，37.8%的患者表示两次注射之间有一定程度的药效减退。便秘是最常见的不良事件（32.6%）。47.2%对erenumab有积极反应并停止治疗患者在6（标准差2.0）周内出现偏头痛反跳。
Erenumab被认为是一种有效且安全的治疗方法。需要进一步研究来调查停药后已取得的改善情况是否会恶化。
• 绝大多数患者体验到erenumab的效果稳定或增强。• Erenumab的疗效通常在治疗的第一个月内显现。• Erenumab的认可度明显高于非特异性预防性药物。• 近40%的患者在两次注射之间有一定程度的药效减退。• 近一半的患者在停药后出现偏头痛反跳。
